BASF, Europe's largest chemicals maker, has officially walked away from its months-long pursuit of rival Evonik, saying the company refused to engage seriously even when BASF signaled it might raise its offer. The announcement sent Evonik shares tumbling 16% to around €18, wiping out much of the premium investors had priced in since the takeover approach became public.
The German chemical giant had been in talks to acquire Evonik, a specialty chemicals company that produces ingredients for pharmaceuticals, coatings, and animal feed. BASF's latest offer valued Evonik at roughly €11.2 billion, or about €24 per share. But BASF said Evonik wouldn't even entertain a moderately higher bid, and that the sticking point wasn't money—it was valuation.
"We made clear we were willing to improve our offer, but Evonik's management wasn't prepared to engage," a BASF spokesperson said. "We ultimately concluded that Evonik's standalone outlook didn't justify paying more."
Why the deal fell apart
Takeover talks between two of Germany's biggest chemical companies were always going to be complicated. Evonik is a major player in specialty chemicals, with a strong position in high-margin products like medical device components and cosmetic ingredients. BASF, by contrast, is more diversified, with a large base chemicals business that is more sensitive to economic cycles.
From BASF's perspective, buying Evonik would have been a way to shift its portfolio toward higher-growth, higher-margin businesses. But Evonik's management apparently saw more value in remaining independent, or at least wanted a price that BASF wasn't willing to pay.
BASF's statement suggests the two sides were far apart on what Evonik is worth. The company said it didn't believe Evonik's standalone outlook justified a higher bid, a clear signal that BASF saw limited synergy potential or growth upside in the deal.
This is a familiar pattern in M&A: when a target's management refuses to engage, acquirers often walk away rather than risk overpaying. As we've seen in other recent deals, like Circle8's abandoned takeover of SThree, a deal can collapse when the buyer loses confidence in the price or the target's willingness to negotiate.
What it means for Evonik investors
The 16% drop in Evonik's share price reflects the loss of the takeover premium. Investors had been betting that BASF would eventually secure a deal at a price well above Evonik's pre-approach trading level. With that hope gone, the stock has fallen back to roughly where it traded before the talks became public.
For Evonik shareholders, the key question now is whether the company can deliver value on its own. BASF's comments suggest it saw limited upside in Evonik's standalone business, which could weigh on sentiment. But Evonik's management has argued that its specialty chemicals portfolio is well-positioned for long-term growth, particularly in areas like healthcare and sustainability.
Investors should also watch whether other buyers emerge. Evonik is a large, strategically important company, and its refusal to engage with BASF doesn't rule out interest from other parties. However, the fact that BASF—a natural buyer—walked away may make it harder for Evonik to attract a rival bidder.
What it means for BASF investors
For BASF shareholders, the collapse of the talks removes a major overhang. A deal of this size would have required significant financing and carried integration risks. By walking away, BASF avoids the risk of overpaying for a business it didn't fully believe in.
BASF's statement that the issue wasn't financing but valuation is reassuring in one sense: it suggests the company is disciplined about capital allocation. But it also raises questions about BASF's growth strategy. The company has been looking for ways to boost its performance, and a major acquisition would have been a bold move.
Instead, BASF will likely focus on organic growth and smaller bolt-on acquisitions. Investors will be watching to see how the company plans to deploy its capital going forward.
Broader market context
The failed takeover comes at a time when European chemical companies are facing headwinds from high energy costs and weak demand. The DAX index, which includes both BASF and Evonik, has been volatile recently, partly due to eurozone inflation staying hot and uncertainty over new takeover rules.
Regulatory changes in Germany have made large deals more complicated, as seen in the Commerzbank takeover talks, where political and regulatory hurdles played a role. While those talks have progressed, the BASF-Evonik situation shows that even when a deal makes strategic sense, it can still fall apart over price.
For investors, the lesson is that takeover premiums are never guaranteed. When a deal collapses, the stock often falls back to pre-approach levels, as we've seen with Evonik. It's a reminder to be cautious about buying stocks purely on the hope of a deal.
What to watch next
Evonik's management will now have to convince investors that it can create value on its own. The company's next earnings report will be closely scrutinized for signs of growth. BASF, meanwhile, will likely face questions about its M&A strategy and whether it has other targets in mind.
For now, the chemicals sector remains in flux, with companies grappling with high costs and uncertain demand. The failed BASF-Evonik deal is a reminder that even the biggest players can't always get what they want.


